Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ETS variant transcription factor 3 like (ETV3L) is a protein-coding gene that encodes a transcriptional regulator belonging to the ETS family of transcription factors. Like other ETS proteins, it contains a conserved DNA-binding domain and is predicted to regulate gene transcription by RNA polymerase II, functioning primarily in the nucleus. ETV3L is involved in DNA binding (specifically to sequences with a central GGA core), and through its activities is implicated in developmental processes and immune response regulation. Little is known about its direct clinical relevance: associated diseases are rare syndromic developmental anomalies, and while the ETS family is broadly implicated in cancer and developmental biology, there is no direct evidence that ETV3L itself acts as a therapeutic target or is modulated by clinically approved drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ETS variant transcription factor 3 like (ETV3L).